Literature DB >> 31134492

Multilayered Heterogeneity of Glioblastoma Stem Cells: Biological and Clinical Significance.

Daniel V Brown1, Stanley S Stylli2,3, Andrew H Kaye2,3, Theo Mantamadiotis4,5.   

Abstract

Glioblastoma is a primary tumor of the brain with a poor prognosis. Pathological examination shows that this disease is characterized by intra-tumor morphological heterogeneity, while numerous and ongoing genomic analysis reveals multiple layers of heterogeneity. Intra-tumor and patient-to-patient heterogeneity is underpinned by cellular, genetic, and molecular heterogeneity, which is thought to be key determinants of time to tumor recurrence and resistance to therapy. The key cell type believed to contribute to the establishment and ongoing evolution of tumor heterogeneity is a glioma stem cell (GSC) subpopulation. In this chapter, we review, highlight, and discuss controversies and clinical relevance of glioblastoma heterogeneity and its cellular basis. Characterization of how cancer stem cells (CSCs) behave is important in understanding how tumors are initiated and how they recur following initial treatment.

Entities:  

Keywords:  Astrocytoma; Brain cancer; Clonal; GBM; GSC; Glioblastoma; Glioma; Heterogeneity; Plasticity; Stem cells; Subclonal

Mesh:

Year:  2019        PMID: 31134492     DOI: 10.1007/978-3-030-14366-4_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

Review 1.  The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions.

Authors:  Richa Shrivastava; Puneet Gandhi; Ragini Gothalwal
Journal:  Clin Transl Oncol       Date:  2022-06-02       Impact factor: 3.340

Review 2.  Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.

Authors:  Lisa Feldman; Christine Brown; Behnam Badie
Journal:  Neuromolecular Med       Date:  2021-10-19       Impact factor: 4.103

Review 3.  Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.

Authors:  Lisa Feldman; Christine Brown; Behnam Badie
Journal:  Neurosurgery       Date:  2021-05-13       Impact factor: 4.654

4.  The nuclear DICER-circular RNA complex drives the deregulation of the glioblastoma cell microRNAome.

Authors:  A Bronisz; A K Rooj; K Krawczyński; P Peruzzi; E Salińska; I Nakano; B Purow; E A Chiocca; J Godlewski
Journal:  Sci Adv       Date:  2020-12-16       Impact factor: 14.136

5.  Functional connectivity within glioblastoma impacts overall survival.

Authors:  Andy G S Daniel; Ki Yun Park; Jarod L Roland; Donna Dierker; James Gross; Joseph B Humphries; Carl D Hacker; Abraham Z Snyder; Joshua S Shimony; Eric C Leuthardt
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

Review 6.  Current Immunotherapeutic Approaches for Malignant Gliomas.

Authors:  Myung-Hoon Han; Choong Hyun Kim
Journal:  Brain Tumor Res Treat       Date:  2022-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.